Key Points
- Luke Miels, a GSK insider, sold 15,579 shares on Feb 13 at GBX 2,160 for £336,506.40 and also sold 4,549 shares on Feb 9 at GBX 2,211 for £100,578.39, indicating recent insider selling.
- GSK shares trade near their 52-week high (opened GBX 2,239; high GBX 2,260) with a market cap of £90.34 billion and a PE of 16.83, and the stock was reported up about 2.5% on the day.
- Analysts are mixed: the consensus rating is Hold with a consensus price target of GBX 1,917.86 (3 Buy, 3 Hold, 1 Sell), though firms like Citigroup and Shore Capital recently raised targets to GBX 2,250 and GBX 2,300 respectively.
GSK plc (LON:GSK - Get Free Report) insider Luke Miels sold 15,579 shares of GSK stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of GBX 2,160, for a total transaction of £336,506.40.
Luke Miels also recently made the following trade(s):
- On Monday, February 9th, Luke Miels sold 4,549 shares of GSK stock. The shares were sold at an average price of GBX 2,211, for a total transaction of £100,578.39.
GSK Stock Up 2.5%
GSK stock opened at GBX 2,239 on Wednesday. The business's 50-day simple moving average is GBX 1,897.25 and its two-hundred day simple moving average is GBX 1,708.84. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The company has a market cap of £90.34 billion, a PE ratio of 16.83, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 2,260.
GSK (LON:GSK - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities analysts anticipate that GSK plc will post 175.980975 EPS for the current year.
Analysts Set New Price Targets
Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft raised their target price on GSK from GBX 1,600 to GBX 1,675 and gave the stock a "hold" rating in a report on Thursday, January 15th. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a report on Wednesday, January 7th. Citigroup boosted their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a "buy" rating in a research note on Monday, February 9th. Shore Capital Group reaffirmed a "buy" rating and issued a GBX 2,300 price objective on shares of GSK in a report on Wednesday, February 4th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,100 price objective on shares of GSK in a research report on Wednesday, January 7th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of GBX 1,917.86.
View Our Latest Analysis on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
